| Chemical Name |
IRL-1620 |
| CAS Number |
142569-99-1 |
| MDL Number |
MFCD00214284 |
| Molecular Formula |
C86H117N17O27 |
| Molecular Weight |
1820.95 |
Introduction of 142569-99-1 :
IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM. IC50 & Target: IC50: 16 pM (Endothelin receptor B), 19 μM (Endothelin receptor A)[1] In Vitro: IRL-1620 is the most potent and specific ligand for the ETB receptor (KiETA/ KiETB=120,000) as judged by the Ki values for ETA (19 μM) and ETB (16 PM) receptors[1].
IRL-1620 is 60 times more selective for the ETB receptor than ET-3 (KiETA/ KiETB=1,900)[1].
In Vivo: IRL-1620 (1-100 nM) induces contractions of the guinea pig trachea. The effective concentration that produces 30 % of 60 mM KCI-induced contraction is estimated to be 28 nM for IRL 1620[1].
IRL-1620 (1-100 nM) increases cytosolic Ca2+ in the vascular endothelium ([Ca]E) with little effect on resting muscle tone, and relaxes the norepinephrine-stimulated tone with an increase in [Ca]E, in rat aorta,[1].
IRL-1620 improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. Rats treated with IRL-1620 significantly reduces the cognitive impairment induced by Aβ. IRL-1620 treatment enhances the number of blood vessels labeled with VEGF compared to vehicle treatment[2].
IRL-1620, restores analgesic tolerance to morphine and oxycodone, but it does not affect morphine and oxycodone induced decrease in NGF/PI3K expression. IRL-1620 attenuates opioid tolerance without the involvement of NGF/PI3K pathway[3].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
